Loading asset research
Ovid Therapeutics Inc. Common Stock
OVIDNasdaq · USD · StocksQuote as of · Exchange session not verified$2.68
+1.90%
Today
OVID
Loading 1D prices…
Market cap
$525.4M
Volume
1.1M
52w high
$3.1152w low
$1.12Company profile
Ovid Therapeutics Inc. Common Stock
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
23
Fiscal year end
1231
CIK
1636651
Session & valuation
Open$2.73
Previous close$2.63
Day high$2.73
Day low$2.64
30-day avg. volume1.5M
Outstanding shares195.3M
Diluted EPS-$0.23
Latest annual period
P/E (trailing)-11.65
P/E (forward)-6.95
Price / book2.37
Beta0.25
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| EOLSEvolus Inc. Common Stock | $517.8M | $297.2M | -17.38% | -$0.80 | -1.01% | Buy |
| ARVNArvinas Inc. Common Stock | $545.2M | $262.6M | -30.85% | -$1.14 | -2.99% | Hold |
| IRDOpus Genetics Inc. Common Stock | $502.5M | $14.2M | -349.33% | -$0.80 | -0.49% | Buy |
| EPRXEupraxia Pharmaceuticals Inc. Common Stock | $556.3M | $0.00 | — | -$1.03 | +4.99% | Buy |
| CTNMContineum Therapeutics Inc. Class A Common Stock | $557.5M | $0.00 | — | -$2.17 | +1.09% | Buy |